We used a novel approach by comprehensively assessing LPS and associated biomarkers, iFABP a marker of intestinal integrity, as well as pro-inflammatory cytokine levels in a well-matched bariatric patient population stratified into subgroups that reflected different stages of NAFLD progression. Here, FABP2 is linked to metabolic dysfunction-associated steatotic liver disease.